Syntonix Pharmaceuticals Inc

Syntonix applies its core technologies to develop long-acting biopharmaceuticals that may be inhaled or injected less frequently, and to discover novel drugs to treat antibody-mediated autoimmune and inflammatory disorders. The resulting proteins, peptides and antibodies are being commercialized through internal development programs and collaborations with biotechnology and pharmaceutical partners.

Further Information: http://www.syntnx.com/